Clinical Research Directory

Participants must meet the following four inclusion criteria: 1\. Overweight or obese patients (meeting any of the following criteria): 1. Obesity: BMI \>=28 kg/m²; 2. Overweight (BMI \>= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease. 2\. Participants must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months. 3\. Age 18-64 years. 4\. Consent to participate and sign the informed consent form. \- Individuals meeting any of the following criteria will be ineligible: 1\. Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo within the next 4 months, weight-loss procedures such as bariatric surgery, acupuncture thread embedding and liposuction; 2. Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt); 3. Allergic or intolerance to inulin-type substances; 4. Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials; 5. Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding; 6. Deemed unsuitable for participation by the investigator's judgment. \-